

Curriculum Vitae

Personal information Fátima Ventura

Work experience

- 1. Employer: INFARMED National Authority of Medicines and Health Products I.P.
 - Start date: 042025
 - End date:
 - Position: Head of Unit, Medicines Evaluation Department/Centralised Procedure Unit
 - Activities: Coordinator of all the activities regarding CHMP and related WPs Country: Portugal
- 2. Employer: General Health Directorate
 - Start date: 112020 End date:

 - Position: Representative of Infarmed Activities: Representative of Infarmed at the Portuguese NITAG for COVID 19 and Flu vaccines: input from regulatory perspectives and status of COVID_19 and Flu vaccines and contribution to advice on national recommendations for COVID_19 and Flu vaccination
- Country: Portugal
 Remployer: INFARMED National Authority of Medicines and Health Products I.P.
 Start date: 032017

 - End date: 032025
 - Position: Head of Unit, Medicines Evaluation Department/Scientific Evaluation Unit
 - Activities:
- Country: Portugal
 4. Employer: INFARMED National Authority of Medicines and Health Products I.P.
 - Start date: 032016
 - End date:
 - Position: Quality Assessor
 - Activities: Internal quality assessor in Biological, Biotechnology and Chemical Human Medicines under the National, Decentralized, Mutual Recognition, and Centralized Procedures, including Marketing Authorisation Applications, Variations and Renovations; Clinical Trials and Variations to Clinical Trials of Experimental Medicinal Products; BSE/TSE issues in the context of medical devices
- Country: Portugal
 Employer: Department of Biochemistry and Human Biology, Faculty of Pharmacy, University of Lisbon
 - Start date: 042007 End date: 022016
 - Position: Assistant Professor
 - Activities:
 - Teaching Biochemistry
 - Supervision of Degree and Post_Graduated Students (Master and PhD) Country: Portugal
- 6. Employer: INFARMED National Authority of Medicines and Health Products, IP
 - Start date: 072010
 - End date:
 - Position: Member of the Human Medicines Evaluation Committee (CAM)
 - Activities:
 - External quality assessor in Chemical and Biological Human Medicines under the National, Decentralized and Mutual Recognition Procedures, including Marketing Authorisation Applications, Variations and Renovations; Clinical Trials and Variations to Clinical Trials of Experimental Medicinal Products; BSE/TSE issues in the context of medical devices
 - Country: Portugal
- 7. Employer: Research Institute for Medicines (iMed.ULisboa) –Metabolism & Genetics Group, Faculty of Pharmacy, University of Lisbon
 - Start date: 072007
 - End date:
 - Position: Researcher
 - Activities:
 - Research in the areas of Molecular and Biochemical Bases of Inborn Errors of Metabolism; Energy Metabolism; Heterologous Expression of Human Proteins involved in lipid metabolism
- Country: Portugal
 Employer: INFARMED National Authority of Medicines and Health Products, IP
 - Start date: 092004

 - End date: 072010 Position: Quality Assessor
 - Activities:
 - External quality assessor in Chemical and Biological Human Medicines under the National, Decentralized, Mutual Recognition procedures, including Marketing Authorisation Applications, variations and renovations; Clinical trials and variations of clinical trials of experimental medicinal products; BSE/TSE issues in the contexto of medical devices
 - Country: Portugal
- 9. Employer: Department of Biochemistry and Human Biology, Faculty of Pharmacy, University of Lisbon
 - Start date: 042002
 - End date: 032007

- Position: College / university teaching professional
- Activities:
 - Teaching Biochemistry
 - Supervision of degree and post_graduated students (Master and PhD)
- Country: Portugal

 Employer: Molecular Pathogenesis Center Unit of Molecular Biology & Experimental Biopathology Molecular and Biochemical Bases of Inborn Errors of Metabolism, Faculty of Pharmacy, University of Lisbon
 - Start date: 042002 End date: 072007
 - Position: Researcher
 - Activities:
 - Research in the Biochemical and Molecular Bases of Inborn Errors of Metabolism; Energy metabolismo; Heterologous expression of human proteins involved in lipid metabolism $\,$
- Country: Portugal
 Employer: INFARMED National Authority of Medicines and Health Products, IP
 - Start date: 012001

 - End date: 042002
 Position: Coordinator at the Technical_Scientific Evaluation Operational Unit of the Human Medicines Evaluation Department
 - Activities:
 - Management and coordination
- Country: Portugal
 Employer: Institute for the Financial and Information Technologies Management of the Health Ministry (IGIF), Health Ministry
 - Start date: 2000
 End date: 2001
 - End date: 2001
 - Position: INFARMED's Representative at the Analysis Commission for the Acquisition of Blood Derived Products (2000)
 - Activities:
 - Consultant
 - Country: Portugal
- 13. The European Agency for the Evaluation of Medicinal Products (EMEA)

 Start date: 2000

 - End date: 2001 Position: Alternate Portuguese Member at the Biologics Working Party (BWP)
 - Activities:
 - Expert
 - Country: United Kingdom
- 14. The European Agency for the Evaluation of Medicinal Products (EMEA)

 Start date: 2000
 - End date: 2000
 - Position: Portuguese member at the Tradenames Ad_Hoc Review Group of the Committee for Proprietary Medicinal Products (CPMP)

 - Activities: Expert
- Country: United Kingdom 15. Employer: Instituto Superior de Ciências da Saúde - Sul
 Start date: 101998

 - End date: 031999
 - Position: College / university teaching professional
 - Teaching Cell Biology to Pharmaceutical Sciences students
- Country: Portugal

 16. Employer: INFARMED National Authority of Medicines and Health Products, IP
 Start date: 041998

 - End date: 082001
 - Position: Regulatory Affairs at the Medicines Department
 - Activities:
 - Managements
 - All aspects of National, Mutual Recognition and Decentratilized Procedures (Present at the monthly meetings of CPMP at EMEA, London)
- Country: Portugal 17. Employer: SDC Pharma, Lda

 - Start date: 101997 End date: 041998
 - Position: Regulatory Affairs
 - Activities:
 - Regulatory Affairs _ preparation and submission of marketing authorisation applications of human medicines at INFARMED Country: Portugal
- 18. European Medicines Agency (EMA) _ Patients' and Consumer's Working Party (PCWP)

 Start date: 032019

 - End date:
 Position: CHMP representative (alternate)
 Activities: Liason between CHMP and PCWP
- Country: Netherlands
 European Medicines Agency (EMA) _ Healthcare Professional's Working Party (HCPWP)
 - Start date: 062016

 - Position: CHMP representative (member)
 Activities: Liason bewteen CHMP and HCPWP
 Country: Netherlands
- 20. European Medicines Agency (EMA) _ Committe for Medicinal Products for Human Use (CHMP)

 Start date: 032016

 - End date:
 - Position: CHMP Alternate Member (PT)
 - Activities: Alternate member from Portugal. Quality assessor in Biological, Biotechnology and Chemical Human Medicines.
 - Country: United Kingdom

Education and training

Subject: Faculty of Pharmacy, University of Lisbon
 Start date: 101993
 End date: 111998

- Oualification: PhD in Pharmacy (Biochemistry)
- Organisation:
- Country: Portugal
 Subject: Metabolism and Genetics Center, Faculty of Pharmacy, University of Lisbon
 - Start date: 1993
 - End date: 1997
 - Qualification: PhD Scholarship from the National Institute for Scientific and Technologic
 - Research
 - Organisation:
- Country: Portugal
 Subject: Academical Medical Centre, University of Amsterdam
 - Start date: 1994

 - End date: 1996 Qualification: PhD Scholarship from the National Institute for Scientific and Technologic Research

 - Organisation: Country: Netherlands
- 4. Subject: Metabolism and Genetics Center, Faculty of Pharmacy, University of Lisbon
 Start date: 1991

 - End date: 1993
 Qualification: Research Fellowship from the National Institute for Scientific Research in the Metabolism and Genetics Center
- Organisation:
 Country: Portugal

 Subject: Faculty of Pharmacy, University of Lisbon
 Start date: 1985

 - End date: 1991
 - Qualification: Degree in Pharmaceutical Sciences (Clinical Chemistry) Organisation:
- Country: Portugal
 Subject: Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM)
 - Start date: 112018
 - End date: 112018
 - Qualification: EU NTC _ Quality Assessment training for Clinical Trials

 - Organisation: Country: Germany
- 7. Subject: European Medicines Agency

 - Start date: 112018 End date:
 - Qualification: Workshop on quality support to accelerated access schemes (i.e. PRIME, Breakthrough Therapies) (webinar)

 - Organisation: Country: United Kingdom
- - Qualification: EMA training on 'European Legislation on Advanced Therapies' (webinar)
 - Organisation:
 - Country: United Kingdom
- 9. Subject: Faculty of Pharmacy, University of PortoStart date: 072018

 - End date: Qualification: European Drug Regulation and Advanced Therapies Organisation:
- Country:

 10. Subject: European Medicines Agency
 - Start date: 062018
 - End date:
 - Qualification: EU Network Regulatory Awareness Session on Medical devices (webinar)
 - Organisation: Country: United Kingdom
- 11. Subject: European Medicines Agency
 Start date: 062018

 - Qualification: BSWP webinar training session 'Basics in Survival Analysis' (webinar e online) Organisation:
- Country: United Kingdom
 12. Subject: European Medicines Agency
 - Start date: 052018

 - End date: Qualification: EMA webinar on regulatory science strategy (webinar)

 - Organisation: Country: United Kingdom
- 13. Subject:
- Start date: 032018
- End date:
- Qualification: EU Network Regulatory awareness session on New Developments in the field of ATMPs (webinar)
- Organisation:
- Country:

 14. Subject: INFARMED National Authority for Medicines and Health Products, I.P.
 Start date: 112017
 End date: 122017

 - Qualification: The risks of corruption and their prevention
- Organisation:
 Country: Portugal

 15. Subject: INFARMED National Authority for Medicines and Health Products, I.P.
 Start date: 112017
 - - End date: Qualification: Cibersecurity
 - Organisation:
- Country: Portugal

 16. Subject: INFARMED National Authority for Medicines and Health Products rodutos de Saúde, I.P. Start date: 102017
 - End date: 102017

 - Qualification: Course on "Ethical, Transparency and Corruption Prevention in Public Administration
 - Organisation:

- Country: Portugal
- 17. Subject: National Institute of Administration _ General Department for Qualification of Employers of Public
 - Start date: 092017
 - End date: 122017
 - Qualification: Certificate in Public Management (FORGEP)
 - Organisation:
- Country: Portugal
 18. Subject: European Medicines Agency
 - Start date: 092017
 - End date:
 - Qualification: EU Network Regulatory Awareness Session Navigating through Biosimilar
 - Development (webinar)
 Organisation:
- Country: United Kingdom
 Subject: European Medicines Agency
 Start date: 092017

 - End date:
 - Qualification: Expert meeting on Adeno Associated Virus (AAV) gene therapy medicinal products (webinar)

 - Organisation: Country: United Kingdom
- 20. Subject: EU_NTC/European Medicines Agency
 Start date: 062017

 - End date: 062017 Qualification: Quality Working Party training for quality assessors (webinar)
- Country: United Kingdom 21. Subject: European Medicines Agency
 - Start date: 062017 End date:
 - Qualification: EU network regulatory awareness session on Early Access (webinar)
 - Organisation: Country: United Kingdom
- 22. Subject: European Medicines Agency
 Start date: 042017

 - End date:
 - Qualification: Orphan Medicines Designation and development in Rare Diseases (webinar) Organisation:
- Country: United Kingdom
 23. Subject: European Medicines Agency
 - Start date: 032017
 - End date:
 - Qualification: Patients' and Consumers' Working Party (PCWP) and Healthcare Professionals' Working Party (HCPWP) joint workshop on personalised medicines
 Organisation:
- Country: United Kingdom
 24. Subject: European Medicines Agency
 Start date: 122016

 - End date: Qualification: EMA Workshop on Adaptive pathways (webinar)

 - Organisation: Country: United Kingdom
- 25. Subject: European Medicines Agency
 - Start date: 122016 End date:
 - Qualification: Assessors training on viral safety evaluation of biotechnological medicinal
 - products (webinar)
 Organisation:
- Country: United Kingdom
 Subject: EU_NTC/European Medicines Agency
 - Start date: 112016
 - End date: 112016
 - Qualification: EU_NTC: EU and International Assessor training on Biosimilars Organisation: Country: United Kingdom
- 27. Subject: European Medicines Agency
 Start date: 112016
 - End date: 112016
 - Qualification: Workshop on scientific and regulatory challenges of genetically modified cell_based cancer immunotherapy products (webinar)
 - Organisation: Country: United Kingdom
- 28. Subject: European Medicines Agency
 - - Start date: 042016
 - End date: Qualification: Orphan designation training for newcomers (webinar) Organisation:
- Country: United Kingdom
 Subject: Faculty of Pharmacy, University of Lisbon
 Start date: 022014

 - End date: 022014 Qualification: VI SPB Clinical Biochemistry Workshop & V SPDM Post_Graduate Training
 - Course _ Peroxisomes and Mitochondria: Players in Cellular Metabolism
 - Organisation:
 - Country: Portugal
- 30. Subject: European Medicines Agency (EMA)

 Start date: 042011

 - End date: 042011 Qualification: Training for Advanced Therapy Medicinal Products Assessors
 - Organisation:
- Country: United Kingdom
 Subject: Biophysics Portuguese Society
 Start date: 102010

 - End date: 102010 Qualification: 9th Short Course of the Portuguese Biophysical Society Protein Folding, Misfolding and Disease
 - Organisation:

- Country: Portugal
 32. Subject: Life and Health Sciences Research Institute, School of Health Sciences, University of Minho
 - Start date: 062009 End date: 062009

 - Qualification: Gene Silencing using RNA interference: lectures and hands_on
 - Organisation:
 - Country: Portugal
- 33. Subject: Center for Neurosciences and Cell Biology, University of Coimbra
 Start date: 052009

 - End date: 052009 Qualification: Integrated Approaches for the Study of Mitochondrial Dynamics Organisation:

 - Country: Portugal
- 34. Subject: Center for Neurosciences and Cell Biology, University of Coimbra
 - Start date: 052009
 - End date: 052009
 - Qualification: International Courses on Toxicology 2009 Mitochondria Between Life and Death
 - Organisation:
 - Country: Portugal
- 35. Subject: ITQB
 - Start date: 032009

 - End date: 032009 Qualification: International Workshop Protein Folding Diseases: From Metabolic Disorders to Neurodegeneration
 - Organisation:
 - Country: Portugal
- 36. Subject: Faculty of Sciences and Technology, Nova University of Lisbon, Department of Chemistry

 Start date: 032007

 - End date: 032007 Qualification: Crystallography of Proteins
 - Organisation:
- Country: Portugal
 Subject: Institute for Membranes and Systems Biology and the Astbury Centre, University of Leeds
 - Start date: 032010 End date: 032010
 - Qualification: Masterclass on Systems Approaches to Membrane Proteins

 - Organisation: Country: United Kingdom
- 38. Subject:
- Start date: 062006
- End date: 062006
- Oualification: 1st International Workshop on Expression, Structure and Function of
- Membrane Proteins
- Organisation: Country: Italy
- 39. Subject: Portuguese Society of Metabolic Disorders, Faculty of Pharmacy, University of Lisbon
 - Start date: 112005
 - End date: 112005
 - Qualification: Post_Graduate Course of Inborn Errors of Metabolism From the Biochemical and Molecular Bases to Clinics, Diagnosis, and Therapeutic Approaches: Mitochondrial Fatty Acid Beta_oxidation Disorders
 - Organisation:
 - Country: Portugal
- 40. Subject: ITQB
 - Start date: 092005
 - End date: 092005
 - Qualification: 1st ESF and MAX_INF2 Course on Membrane Proteins: The Rocky Road from Gene to Structure
 - Organisation:
- Organisation:
 Country: Portugal

 41. Subject: Portuguese Society of Metabolic Disorders, Faculty of Pharmacy, University of Lisbon
 - Start date: 072005
 - End date: 072005
 - Qualification: Post_Graduate Course of Inborn Errors of Metabolism From the Biochemical and Molecular Bases to Clinics, Diagnosis, and Therapeutic Approaches: Organic Acidurias
 - Organisation:
- Country: Portugal
 Subject: Portuguese Society of Metabolic Disorders, Faculty of Pharmacy, University of Lisbon
 - Start date: 052005 End date: 052005

 - Qualification: Post_Graduate Course of Inborn Errors of Metabolism From the Biochemical and Molecular Bases to Clinics, Diagnosis, and Therapeutic Approaches: Defect of Urea Cycle Organisation:
 - Country: Portugal
- 43. Subject: IST
 - Start date: 052005 End date: 052005

 - Qualification: Second Meeting of the COST Working Group Principles of Membrane Protein Folding and Stability
 - Organisation:
- Country: Portugal
 Subject: Portuguese Society of Metabolic Disorders, Faculty of Pharmacy, University of Lisbon
 - Start date: 042005 End date: 042005

 - Qualification: Post_Graduate Course of Inborn Errors of Metabolism From the Biochemical and Molecular Bases to Clinics, Diagnosis, and Therapeutic Approaches: Defect of Pyruvate
 - Dehydrogenase Organisation:
 - Country:
- 45. Subject: Faculty of Pharmacy, University of Lisbon

 - Start date: 062003 End date: 062003
 - Qualification: International Symposium on Stem Cells and Regenerative
 - Organisation: Country:
- 46. Subject: Institute Pasteur
 - Start date: 102000

- End date: 102000
- Qualification: Pharmacogenetics and Pharmacogenomics
- Organisation Country: France
- 47. Subject: IBC
 - Start date: 092000 End date: 092000
 - Qualification: IBC's 9th Annual International Conference _ Protecting and Exploiting _ Utilising biotechnological patents to the full

 - Organisation:
- Country: Denmark

 48. Subject: The European Agency for the Evaluation of Medicinal Products (EMEA)
 - Start date: 052000 End date: 052000
 - Qualification: Human TSEs and Plasma Derived Medicinal Products
 - Organisation:
- Country: United Kingdom
 49. Subject: University of Essen
 Start date: 042000

 - End date: 042000
 - Qualification: First International Conference on Gene Technology & Skin Gene Therapy
 - Organisation:
- Country: Germany 50. Subject: Agencia Española del Medicamento

 - Start date: 111999 End date: 111999
 - Qualification: Meeting on the use of pharmacogenetics in drug development
 - Organisation: Country: Spain
- - End date: 101999
 - Qualification: Development and Clinical Progress of DNA Vaccines
 - Organisation:
- Country: Germany
 Subject: European Association of the Plasma Products Industry (EAPPI) and European Plasma
 - Fractionation Association (EPFA) Start date: 101999
 - End date: 101999
 - \bullet Qualification: 6th Annual EAPPI EPFA $_$ Regulatory Affairs Symposium $_$ Quality & Safety of Plasma Products
 - Organisation
 - Country: France
- 53. Subject: IIR
 - Start date: 041999 End date: 041999
 - Qualification: Introduction to European Regulatory Affairs
 - Organisation:
 - Country: United Kingdom
- 54. Subject: Cambridge Healthtech Institute
 Start date: 021999

 - End date: 021999 Qualification: TSE Perception vs. Reality
 - Organisation:
- Country: United States 55. Subject: Cambridge Healthtech Institute
 - Start date: 021999 End date: 021999

 - Qualification: Blood Safety & Screening
 - Organisation:
 - Country: United States
- 56. Subject:
- Start date: 101998 End date: 101998
- Qualification: 2nd European Course of Pre_Clinical Assessors Organisation:
- Country: Portugal
 Subject: INFARMED
 - Start date: 051998
 - End date: 051998 Qualification: Methodologies in Pharmacovigilance
 - Organisation: Country: Portugal
- 58. Subject: Faculty of Sciences and Technology, Nova University of Lisbon, Department of Chemistry, Costa da Caparica, Portugal & Toxicology Institute, University of Tübingen , Germany
 • Start date: 101992

 - End date: 101992 Qualification: High Performance Liquid Chromatography Professional Course
 - Organisation:
 - Country: Portugal

Additional information

Publications

- 22. Cunha J, **Ventura FV**, Charrueau C, Ribeiro AJ.Alternative routes for parenteral nucleic acid delivery and related hurdles: highlights in RNA delivery. Expert Opin Drug Deliv. 2024 Oct;21(10):1415-1439. doi: 10.1080/17425247.2024.2405207.
- 21. Madeira CA, Anselmo C, Costa JM, Bonito CA, Ferreira RJ, Santos DJVA, Wanders RJ, Vicente JB, **Ventura FV**, Leandro P. Functional and structural impact of 10 ACADM missense mutations on human medium chain acyl-Coa dehydrogenase. Biochim Biophys Acta Mol Basis Dis. 2023 Oct;1869(7):166766. doi: 10.1016/j.bbadis.2023.166766
- 20. Souto EB, Silva GF, Dias_Ferreira J, Zielinska A, **Ventura F**, Durazzo A, Lucarini M, Novellino E, Santini A. Nanopharmaceutics: Part I_Clinical Trials Legislation and Good Manufacturing Practices (GMP) of Nanotherapeutics in the EU. Pharmaceutics. 2020 Feb 11;12(2):146. doi: 10.3390/pharmaceutics12020146.
- 19. Souto EB, Silva GF, Dias_Ferreira J, Zielinska A, **Ventura F**, Durazzo A, Lucarini M, Novellino E, Santini A. Nanopharmaceutics: Part I_Clinical Trials Legislation and Good Manufacturing Practices (GMP) of Nanotherapeutics

- in the EU. Pharmaceutics, 2020 Feb 11:12(2):146, doi: 10.3390/pharmaceutics12020146,
- 18. Janeiro P, Jotta R, Ramos R, Florindo C, **Ventura FV**, Vilarinho L, Tavares de Almeida I, Gaspar A. Follow_up of fatty acid β _oxidation disorders in expanded newborn screening era. Eur J Pediatr. 2019 Mar;178(3):387_394. doi: 10.1007/s00431_018_03315_2.
- 17. Pelfrene E, Harvey Allchurch M, Ntamabyaliro N, Nambasa V, **Ventura FV**, Nagercoil N, Cavaleri M. The European Medicines Agency's scientific opinion on oral fexinidazole for human African trypanosomiasis. PLoS Negl Trop Dis. 2019 Jun 27;13(6):e0007381. doi: 10.1371/journal.pntd.0007381. doi: 10.1371/journal.pntd.0007381.
- 16. Bonito CA, Nunes J, Leandro J, Louro F, Leandro P, **Ventura FV**, Guedes RC. Unveiling the Pathogenic Molecular Mechanisms of the Most Common Variant (p.K329E) in Medium Acyl_CoA Dehydrogenase Deficiency by in Vitro and in Silico Approaches. Biochemistry. 2016. 55(51):7086_7098. doi: 10.1021/acs.biochem.6b00759.
- 15. Bonito CA, Leandro P, Guedes R, **Ventura FV**. Insights on Medium_chain acyl_CoA dehydrogenase structure by Molecular Dynamics simulations. Chemical Biology & Drug Design. 2016. doi: 10.1111/cbdd.12755.
- 14. Houten SM, Violante S, **Ventura FV**, Wanders RJ. The Biochemistry and Physiology of Mitochondrial Fatty Acid β_Oxidation and Its Genetic Disorders. Annual Review Physiol. 78:23_44, 2016. doi: 10.1146/annurev_physiol_021115_105045.
- 13. **Ventura FV**, Leandro P, Luz A, Rivera IA, Silva MF, Ramos R, Rocha H, Lopes A, Fonseca H, Gaspar A, Diogo L, Martins E, Leão_Teles E, Vilarinho L, Tavares de Almeida I. Retrospective study of the medium_chain acyl_CoA dehydrogenase deficiency in Portugal. Clinical Genetics. 2014. doi: 10.1111/cge.12227.
- 12. Violante S, Ijlst L, Te Brinke H, Koster J, Tavares de Almeida I, Wanders RJ, **Ventura FV**, Houten SM. Peroxisomes contribute to the acylcarnitine production when the carnitine shuttle is deficient. Biochimica et Biophys Acta. 1831(9):1467_74, 2013; doi: 10.1016/j.bbalip.2013.06.007.
- 11. Violante S, Ijlst L, Ruiter J, Koster J, van Lenthe H, Duran M, de Almeida IT, Wanders RJ, Houten SM, **Ventura FV**. Substrate specificity of human carnitine acetyltransferase: Implications for fatty acid and branched_chain amino acid metabolism. Biochimica et Biophysica Acta. 1832(6):773_9, 2013; doi: 10.1016/j.bbadis.2013.02.012.
- 10. Violante S, Ijlst L, Te Brinke H, Tavares de Almeida I, Wanders RJ, **Ventura FV**, Houten SM. Carnitine palmitoyltransferase 2 and carnitine/acylcarnitine translocase are involved in the mitochondrial synthesis and export of acylcarnitines. FASEB J. 27(5):2039_44, 2013; doi: 10.1096/fj.12_216689.
- 9. Violante S, IJlst L, van Lenthe H, Tavares de Almeida I, Wanders RJ, **Ventura FV**. Carnitine Palmitoyltransferase 2: New Insights on the Substrate Specificity and Implications for Acylcarnitine Profiling. Biochimica et Biophysica Acta 1802: 728_732, 2010. doi:10.1016/j.bbadis.2010.06.002.
- 8. **Ventura FV**, Tavares de Almeida I, Wanders RJA. Inhibition of adenine nucleotide transport in rat liver mitochondria by long_chain acyl_coenzyme A ß_oxidation intermediates. Biochemical and Biophysical Research Communications 352: 873_878, 2007. doi:10.1016/j.bbrc.2006.11.109.
- 7. **Ventura FV**, Ruiter J, IJlst L, Tavares de Almeida I, Wanders RJA. Differential inhibitory effect of long_chain acyl_CoA esters on succinate and glutamate transport into rat liver mitochondria and its possible implications for long_chain fatty acid oxidation defects. Molecular Genetics and Metabolism 86: 344_352, 2005. doi:10.1016/j.ymgme.2005.07.030.
- 6. **Ventura FV**, Costa CG, Ruiter JPN, Allers P, IJlst L, Tavares de Almeida I, Duran M, Jakobs C, Wanders RJA. Quantitative acylcarnitine profiling of [U_13C]palmitic acid B_0 oxidation in human fibroblasts: an improved tool for the diagnosis of fatty acid oxidation defects. Clinica Chimica Acta 281: 1_17 , 1999. doi:10.1016/S0009_8981(98)00188_0.
- 5. **Ventura FV**, Ruiter JPN, IJlst L, Tavares de Almeida I, Wanders RJA. Lactic acidosis in long_chain fatty acid β_oxidation disorders. Journal of Inherited Metabolic Disease 21: 645_654, 1998. doi:10.1023/A:1005480516801.
- 4. **Ventura FV**, IJlst L, Ruiter JPN, Ofman R, Costa CG, Jakobs C, Duran M, Tavares de Almeida I, Bieber L, Wanders RJA. Carnitine palmitoyltransferase II specificity towards β_oxidation intermediates: evidence for a reverse carnitine cycle in mitochondria. European Journal of Biochemistry 253: 614_618, 1998. doi:10.1046/j.1432_1327.1998.2530614.x.
- 3. **Ventura FV**, Costa CG, IJlst L, Dorland L, Duran M, Jakobs C, Tavares de Almeida I, Bieber L, Wanders RJA. Broad specificity of carnitine palmitoyltransferase II towards long_chain acyl_CoA β_oxidation intermediates and its practical approach to the synthesis of various long_chain acylcarnitines. Journal of Inherited Metabolic Disease 20: 423_426, 1997. doi: 10.1023/A:1005315003913.
- 2. **Ventura FV**, Ruiter JPN, IJIst L, Tavares de Almeida I, Wanders RJA. Inhibitory effect of $3_hydroxy$ acyl_CoAs and other long_chain fatty acid $\beta_oxidation$ intermediates in mitochondrial oxidative phosphorylation. Journal of Inherited Metabolic Disease 19: $161_0.164$, 1996. doi:10.1007/BF01799419.
- 1. **Ventura FV**, Ruiter JPN, IJIst L, Tavares de Almeida I, Wanders RJA. Inhibition of oxidative phosphorylation by palmitoyl_CoA in digitonin permeabilized fibroblasts: implications for long_chain fatty acid β _oxidation disorders. Biochimica et Biophysica Acta Molecular Basis of Disease 1272: 14_20, 1995. doi:10.1016/0925_4439(95)00064_B, Since 1996 published 19 original communications, in the form of abstract, in Scientific Meetings Proceedings published in International Journals
- Since 1992 presented/contributed for more than 24 oral communications (10 invited) at International (13) and Nacional (10) meetings
- Since 1993 published more than 50 original communications, in the form of panel in various International (34) and National (13) meetings

Projects

- Understand to treat: Combining in vitro and in silico strategies to explore new therapeutic approaches to the most common mitochondrial fatty acid beta_oxidation disorder (mFAOD)" (PTDC/BIA_BQM/29570/2017) (Principal Investigator)
- Medium_chain Acyl_Coenzyme A Dehydrogenase Deficiency: Functional and Structural Characterization of Mutant Proteins (SPDM; 2010_2011) (Principal Investigator)
- Production of a Stable Form of Human Phenylalanine Hydroxylase: Towards the 3D Structure Determination (PDTC/QUI/64023/2006; 2009_2012) (Team member)
- Inborn Errors of Metabolism: Aminoacidopathies and Organic Aciduria (PMCT/C/SAU/1540/92; 1992_1994)

(Team member)

Aminoacidopathies: detection and chemical characterization of the Inborn Errors of the Aminoacids' Metabolism (INIC; 1991_1993) (Team member)

Memberships

- The Society for the Study of Inborn Errors of Metabolism (SSIEM) (1995_ 1999; 2007_2009; 2013_)
 Ordem dos Farmacêuticos, Sociedade Farmacêutica Lusitana (Sócio n.º L_8271_ Secção Regional de Lisboa) (since 1998)
 • Portuguese Society of Metabolic Disorders (since 2002)
- Biochemistry Portuguese Society (since 2002)
 Biophysics Portuguese Society (since 2010)

Other Relevant Information

I have long been interested in the elucidation of the pathogenesis of mitochondrial fatty acid beta-oxidation (FAO) disorders, namely the interaction mechanisms between FAO, energy metabolism and the carnitine cycle. In the last years, she expanded her studies into the in vitro and in silico characterization of the wild-type and various disease-causing mutants of the medium-chain acyl-CoA dehydrogenase, an enzyme of FAO. The ultimate goal is to define structural-functional markers for the screening for small molecules able to rescue the variant enzymes showing in vitro to be affected by misfolding.